Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male, aged 18-70 years (both inclusive) at the time of signing informed consent~* Patients with the diagnosis of congenital haemophilia B with factor IX activity below or equal to 2%, based on medical records~* History of more than 150 exposures days to any factor IX containing products~Exclusion Criteria:~* Known history of factor IX inhibitors~* Inhibitors to factor IX (above or equal to 0.6 BU) at screening measured by the Nijmegen modified Bethesda method~* Immunocompromised (CD4+ T cells below or equal to 200/μL)~* Known congenital or acquired coagulation disorders other than haemophilia B~* Body mass index above 35 kg/m\^²

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- N9-GP (Type: EXPERIMENTAL): None
- ALPROLIX® (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).